Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Kropff M, et al. Among authors: lang n. Br J Haematol. 2007 Aug;138(3):330-7. doi: 10.1111/j.1365-2141.2007.06656.x. Br J Haematol. 2007. PMID: 17614819 Free article. Clinical Trial.
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Kropff MH, et al. Among authors: lang n. Br J Haematol. 2003 Aug;122(4):607-16. doi: 10.1046/j.1365-2141.2003.04473.x. Br J Haematol. 2003. PMID: 12899716 Free article. Clinical Trial.
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J. Bisping G, et al. Among authors: lang n. Blood. 2006 Mar 1;107(5):2079-89. doi: 10.1182/blood-2004-11-4250. Epub 2005 Nov 8. Blood. 2006. PMID: 16278310 Free article.
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H. Straka C, et al. Among authors: lang n. Haematologica. 2016 Nov;101(11):1398-1406. doi: 10.3324/haematol.2016.151860. Epub 2016 Aug 4. Haematologica. 2016. PMID: 27662018 Free PMC article. Clinical Trial.
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI).
Carberry J, Petrie MC, Lee MMY, Stanley B, Brooksbank KJM, Campbell RT, Good R, Jhund PS, Kellman P, Lang NN, Lindsay MM, Mangion K, Gardner RS, Mark PB, Meyer B, O'Donnell J, Orchard V, Shaukat A, Watkins S, McConnachie A, McMurray JJV, Welsh P, Sattar N, Berry C, Docherty KF. Carberry J, et al. Among authors: lang nn. Eur J Heart Fail. 2024 Dec 15. doi: 10.1002/ejhf.3560. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39675781
1,665 results